A Multicenter, Open-label, Dose-escalation, Phase 1 Trial to Investigate the Tolerability and Safety of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Cedazuridine/decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
Most Recent Events
- 17 Apr 2024 Planned End Date changed from 31 Dec 2023 to 31 Jan 2026.
- 17 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Jan 2026.
- 14 Jan 2022 Planned End Date changed from 1 Dec 2021 to 31 Dec 2023.